ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Epidemiology of Pulmonary and Extrapulmonary Nontuberculous Mycobacteria Infections at 4 US Emerging Infections Program Sites: A 6-Month Pilot.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Outcomes of non-tuberculous mycobacterial infection of the bone, joint and soft tissue: a seven-year multicentre retrospective study.Infection · 2026Article
- Proportions ofJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Clinical characteristics of nontuberculous mycobacterial infections among people with presumptive tuberculosis in India: a multicenter study (2021-2025).The Lancet regional health. Southeast Asia · 2026Article
- Pharmacokinetics of minocycline with and without rifampicin co-administration in patients with nontuberculous mycobacterial disease.The Journal of antimicrobial chemotherapy · 2026Article
- Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.The Medical journal of Australia · 2026Observational
- Evaluation of the post-antibiotic effect againstMicrobiology spectrum · 2026Article
- Physical compatibility of omadacycline with intravenous agents used in the treatment of Mycobacteroides abscessus pulmonary disease.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Article
- Costs of Extrapulmonary Nontuberculous Mycobacteria Disease, Denmark, 2005-2017.Emerging infectious diseases · 2026Article
- Recovery of nontuberculous mycobacteria from non-cystic fibrosis respiratory specimens using a decontamination-free selective agar.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Epidemiology and Drug Susceptibility of Nontuberculous Mycobacteria in the Province of Pavia (Northern Italy): An Overview.Microorganisms · 2025Article
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- IFNGR1, IRF8 genetic polymorphisms modulate the susceptibility of non-tuberculous mycobacteria pulmonary disease and influence the patients' treatment outcomes and immune status.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Moving Beyond the Silos of Opportunistic Pathogen and Disinfection Byproduct Research to Improve Drinking Water System Management.Environmental science & technology · 2025Review
- An Integrated Mycobacterial CT Imaging Dataset with Multispecies Information.Scientific data · 2025Article
- Non-InvasivePharmaceutics · 2025Article
- Extrapulmonary Nontuberculous Mycobacteria Infection: The New-Age Neglected Infectious Disease.Cureus · 2025Review
- Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan.ERJ open research · 2025Article
- Epidemiology of nontuberculous mycobacteria in the Finger Lakes region of New York.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory- and population-based NTM surveillance.
methodsThe Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review.
resultsOverall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure.
conclusionsActive, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.